Woerman, Amanda L.
Kazmi, Sabeen A.
Patel, Smita
Freyman, Yevgeniy
Oehler, Abby
Aoyagi, Atsushi
Mordes, Daniel A.
Halliday, Glenda M.
Middleton, Lefkos T.
Gentleman, Steve M.
Olson, Steven H.
Prusiner, Stanley B.
Funding for this research was provided by:
National Institute on Aging (AG002132, AG031220)
Glenn Foundation for Medical Research
Daiichi-Sankyo
National Health and Medical Research Council of Australia
Article History
Received: 11 July 2017
Revised: 1 August 2017
Accepted: 2 August 2017
First Online: 28 August 2017
Compliance with ethical standards
:
: The Institute for Neurodegenerative Diseases has a research collaboration with Daiichi Sankyo (Tokyo, Japan). SBP is the chair of the Scientific Advisory Board of Alzheon, Inc., which has not contributed financial or any other support to these studies.
: Animals were maintained in an AAALAC-accredited facility in compliance with the Guide for the Care and Use of Laboratory Animals. All procedures used in this study were approved by the University of California, San Francisco, Institutional Animal Care and Use Committee.
: This work was supported by grants from the National Institutes of Health (AG002132 and AG031220), as well as by gifts from the Glenn Foundation, Daiichi Sankyo, the Dana Foundation, the Henry M. Jackson Foundation, the Mary Jane Brinton Fund, the Rainwater Charitable Foundation, the Schott Foundation for Public Education, and the Sherman Fairchild Foundation. The Massachusetts Alzheimer’s Disease Research Center is supported by the National Institutes of Health (AG005134); the Parkinson’s UK Brain Bank at Imperial College London is funded by Parkinson’s UK, a charity registered in England and Wales (948776) and in Scotland (SC037554); and the Sydney Brain Bank is supported by Neuroscience Research Australia and the University of New South Wales. Glenda M. Halliday is a National Health and Medical Research Council of Australia Senior Principal Research Fellow (1079679).